Acute Pneumonia

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 1, Issue , 2014, Pages 823-846.e5

  Ellison, Richard T ^a   Donowitz, Gerald R ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aspiration; Bronchoscopy; Chlamydia pneumoniae; CRB 65; Legionella pneumophila; Mycoplasma pneumoniae; Pneumonia; Pneumonia severity index (PSI); Procalcitonin; Streptococcus pneumoniae

Indexed keywords

EID: 84944612484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00069-2     Document Type: Chapter

References (409)

1. Osler W The Principles and Practice of Medicine 1901, Appleton, New York. 4th ed.
2. Minino AM, Murphy SL, Xu J, et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011, 59:1-126.
3. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011, 184:957-963.
4. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
5. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1073-1080.
6. Reynolds HY Pulmonary host defenses: state of the art. Chest 1989, 95(3 suppl):223S-230S.
7. Sibille Y, Reynolds HY Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990, 141:471-501.
8. Ganz T Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002, 109:693-697.
9. Wright JR Immunomodulatory functions of surfactant. Physiol Rev 1997, 77:931-962.
10. Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000, 173:39-51.
11. Lohmann-Matthes ML, Steinmuller C, Franke-Ullmann G Pulmonary macrophages. Eur Respir J 1994, 7:1678-1689.
12. Little FF, Wilson KC, Berman JS, et al. Lymphocyte- and macrophage-mediated inflammation in the lung. Fishman's Pulmonary Diseases and Disorders 2008, 291-305. McGraw-Hill, New York. 4th ed. A.P. Fishman, J.A. Elias, J.A. Fishman (Eds.).
13. MacNee W, Selby C Neutrophil kinetics in the lungs. Clin Sci (Lond) 1990, 79:97-107.
14. Reynolds HY Advances in understanding pulmonary host defense mechanisms: dendritic cell function and immunomodulation. Curr Opin Pulm Med 2000, 6:209-216.
15. Prince AS, Mizgerd JP, Wiener-Kronish J, et al. Cell signaling underlying the pathophysiology of pneumonia. Am J Physiol Lung Cell Mol Physiol 2006, 291:L297-L300.
16. Strieter RM, Standiford TJ, Huffnagle GB, et al. "The good, the bad, and the ugly." The role of chemokines in models of human disease. J Immunol 1996, 156:3583-3586.
17. Chaudhuri N, Whyte MK, Sabroe I Reducing the toll of inflammatory lung disease. Chest 2007, 131:1550-1556.
18. Puren AJ, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995, 107:1342-1349.
19. Strieter RM, Belperio JA, Keane MP Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 2003, 16:193-198.
20. Mizgerd JP Acute lower respiratory tract infection. N Engl J Med 2008, 358:716-727.
21. Diamond G, Legarda D, Ryan LK The innate immune response of the respiratory epithelium. Immunol Rev 2000, 173:27-38.
22. Huxley EJ, Viroslav J, Gray WR, et al. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am J Med 1978, 64:564-568.
23. Green GM, Carolin D The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages. N Engl J Med 1967, 276:421-427.
24. Sopori M Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002, 2:372-377.
25. MacGregor RR Alcohol and immune defense. JAMA 1986, 256:1474-1479.
26. Schopf RE, Trompeter M, Bork K, et al. Effects of ethanol and acetaldehyde on phagocytic functions. Arch Dermatol Res 1985, 277:131-137.
27. Zhang P, Bagby GJ, Happel KI, et al. Pulmonary host defenses and alcohol. Front Biosci 2002, 7:d1314-d1330.
28. Nelson S, Mason CM, Kolls J, et al. Pathophysiology of pneumonia. Clin Chest Med 1995, 16:1-12.
29. Warshauer D, Goldstein E, Akers T, et al. Effect of influenza viral infection on the ingestion and killing of bacteria by alveolar macrophages. Am Rev Respir Dis 1977, 115:269-277.
30. Nelson S, Chidiac C, Bagby G, Summer WR Endotoxin-induced suppression of lung host defenses. J Med 1990, 21:85-103.
31. Phair J, Palella FJ Host impairments associated with human immunodeficiency virus infection. Respiratory Infections 2001, 59-66. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. M.S. Niederman, G.A. Sarosi, J. Glassroth (Eds.).
32. Mason CM The pathogenesis and presentation of nosocomial pneumonia. Crit Care Rev 1991, 2:145-155.
33. Nelson S, Summer WR, Jakab GJ Aminophylline-induced suppression of pulmonary antibacterial defenses. Am Rev Respir Dis 1985, 131:923-927.
34. Esposito AL Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis 1984, 130:857-862.
35. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012, 56:3819-3825.
36. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009, 301:2120-2128.
37. Sultan N, Nazareno J, Gregor J Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008, 22:761-766.
38. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010, 152:418-425.
39. Ehrlich R, Henry MC Chronic toxicity of nitrogen dioxide, I. Effect on resistance to bacterial pneumonia. Arch Environ Health 1968, 17:860-865.
40. Huber GL, LaForce FM, Mason RJ, et al. Impairment of pulmonary bacterial defense mechanisms by immunosuppressive agents. Surg Forum 1970, 21:285-286.
41. LaForce FM, Mullane JF, Boehme RF, et al. The effect of pulmonary edema on antibacterial defenses of the lung. J Lab Clin Med 1973, 82:634-648.
42. Perbet S, Mongardon N, Dumas F, et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med 2011, 184:1048-1054.
43. Gyetko MR, Toews GB Immunology of the aging lung. Clin Chest Med 1993, 14:379-391.
44. Meyer KC, Ershler W, Rosenthal NS, et al. Immune dysregulation in the aging human lung. Am J Respir Crit Care Med 1996, 153:1072-1079.
45. Geppert EF Chronic and recurrent pneumonia. Semin Respir Infect 1992, 7:282-288.
46. Beck CS, Heiner DC Selective immunoglobulin G4 deficiency and recurrent infections of the respiratory tract. Am Rev Respir Dis 1981, 124:94-96.
47. Donabedian H, Gallin JI The hyperimmunoglobulin E recurrent-infection (Job's) syndrome: a review of the NIH experience and the literature. Medicine (Baltimore) 1983, 62:195-208.
48. Heffelfinger JD, Davis TE, Gebrian B, et al. Evaluation of children with recurrent pneumonia diagnosed by World Health Organization criteria. Pediatr Infect Dis J 2002, 21:108-112.
49. Owayed AF, Campbell DM, Wang EE Underlying causes of recurrent pneumonia in children. Arch Pediatr Adolesc Med 2000, 154:190-194.
50. Leigh MW, Pittman JE, Carson JL, et al. Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. Genet Med 2009, 11:473-487.
51. Gibson RL, Burns JL, Ramsey BW Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
52. Metlay JP, Stafford RS, Singer DE National trends in the use of antibiotics by primary care physicians for adult patients with cough. Arch Intern Med 1998, 158:1813-1818.
53. Metlay JP, Kapoor WN, Fine MJ Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997, 278:1440-1445.
54. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997, 157:1453-1459.
55. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-1718.
56. Chertow DS, Memoli MJ Bacterial coinfection in influenza: a grand rounds review. JAMA 2013, 309:275-282.
57. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
58. Monaco M, Antonucci R, Palange P, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis 2005, 11:1647-1648.
59. Dorff GJ, Rytel MW, Farmer SG, et al. Etiologies and characteristic features of pneumonias in a municipal hospital. Am J Med Sci 1973, 266:349-358.
60. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008, 31:1274-1284.
61. Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005, 41:345-351.
62. Johansson N, Kalin M, Hedlund J Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011, 43:609-615.
63. Griffith DE, Mazurek GH Pneumonia in chronic obstructive lung disease. Infect Dis Clin North Am 1991, 5:467-484.
64. Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996, 154:1456-1461.
65. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
66. Wallace JM, Rao AV, Glassroth J, et al. Respiratory illness in persons with human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. Am Rev Respir Dis 1993, 148(6 pt 1):1523-1529.
67. Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008, 47:1345-1353.
68. Hull MW, Phillips P, Montaner JS Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008, 134:1287-1298.
69. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medical Association of the Infectious Diseases Society of America. Available at, Accessed May 7, 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
70. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006, 43:90-98.
71. Buchacz K, Baker RK, Palella FJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010, 24:1549-1559.
72. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995, 333:845-851.
73. + T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med 1995, 155:1537-1542.
74. Jones RN Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51(suppl 1):S81-S87.
75. Marrie TJ, Haldane EV, Faulkner RS, et al. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly?. J Am Geriatr Soc 1985, 33:671-680.
76. Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003, 82:159-169.
77. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
78. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007, 167:1393-1399.
79. Bartlett JG, Finegold SM Anaerobic infections of the lung and pleural space. Am Rev Respir Dis 1974, 110:56-77.
80. Woodhead M Management of pneumonia in the outpatient setting. Semin Respir Infect 1998, 13:8-16.
81. Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic?. Arch Intern Med 1999, 159:1082-1087.
82. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005, 60:672-678.
83. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010, 50:202-209.
84. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
85. Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000, 31:869-874.
86. Miyashita N, Shimizu H, Ouchi K, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008, 14:CR171-CR176.
87. Musher DM, Montoya R, Wanahita A Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004, 39:165-169.
88. Bartlett JG Decline in microbial studies for patients with pulmonary infections. Clin Infect Dis 2004, 39:170-172.
89. Reimer LG, Carroll KC Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998, 26:742-748.
90. George RB, Ziskind MM, Rasch JR, et al. Mycoplasma and adenovirus pneumonias: comparison with other atypical pneumonias in a military population. Ann Intern Med 1966, 65:931-942.
91. Reimann H The Pneumonias 1938, Saunders, Philadelphia.
92. Solomon S Primary Friedlander pneumonia. JAMA 1937, 108:937-947.
93. Wong LK, Barry AL, Horgan SM Comparison of six different criteria for judging the acceptability of sputum specimens. J Clin Microbiol 1982, 16:627-631.
94. Rein MF, Gwaltney JM, O'Brien WM, et al. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA 1978, 239:2671-2673.
95. Hendley JO, Sande MA, Stewart PM, et al. Spread of Streptococcus pneumoniae in families, I. Carriage rates and distribution of types. J Infect Dis 1975, 132:55-61.
96. Wallace RJ, Musher DM, Martin RR Hemophilus influenzae pneumonia in adults. Am J Med 1978, 64:87-93.
97. Levin DC, Schwarz MI, Matthay RA, et al. Bacteremic Hemophilus influenzae pneumonia in adults: a report of 24 cases and a review of the literature. Am J Med 1977, 62:219-224.
98. Davidson M, Tempest B, Palmer DL Bacteriologic diag-nosis of acute pneumonia: comparison of sputum, transtracheal aspirates, and lung aspirates. JAMA 1976, 235:158-163.
99. Murdoch DR Diagnosis of Legionella infection. Clin Infect Dis 2003, 36:64-69.
100. Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996, 124:585-599.
101. Bollee G, Sarfati C, Thiery G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007, 132:1305-1310.
102. Murdoch DR Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004, 112:713-727.
103. Mahony JB Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008, 21:716-747.
104. Diederen BM, Van Der Eerden MM, Vlaspolder F, et al. Detection of respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community acquired pneumonia. Scand J Infect Dis 2009, 41:45-50.
105. Baselski VS, Wunderink RG Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev 1994, 7:533-558.
106. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005, 24:241-249.
107. Chastre J, Fagon JY, Bornet-Lecso M, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995, 152:231-240.
108. Broughton WA, Middleton RM, Kirkpatrick MB, et al. Bronchoscopic protected specimen brush and bronchoalveolar lavage in the diagnosis of bacterial pneumonia. Infect Dis Clin North Am 1991, 5:437-452.
109. Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995, 151:1878-1888.
110. Michaud S, Suzuki S, Harbarth S Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 166:1320-1325.
111. Broaddus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 102:747-752.
112. Pisani RJ, Wright AJ Clinical utility of bronchoalveolar lavage in immunocompromised hosts. Mayo Clin Proc 1992, 67:221-227.
113. Baughman RP, Dohn MN, Loudon RG, et al. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest 1991, 99:92-97.
114. Avni T, Levy I, Sprecher H, et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012, 50:3652-3658.
115. Baughman R Use of bronchoscopy in the diagnosis of infection in the immunocompromised host. Thorax 1994, 49:3-7.
116. Prechter GC, Prakash UB Bronchoscopy in the diagnosis of pulmonary histoplasmosis. Chest 1989, 95:1033-1036.
117. Gerbeaux P, Ledoray V, Boussuges A, et al. Diagnosis of nosocomial pneumonia in mechanically ventilated patients: repeatability of the bronchoalveolar lavage. Am J Respir Crit Care Med 1998, 157:76-80.
118. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006, 355:2619-2630. Canadian Critical Care Trials Group.
119. el-Ebiary M, Torres A, Gonzalez J, et al. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993, 148(6 pt 1):1552-1557.
120. Jourdain B, Novara A, Joly-Guillou ML, et al. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995, 152:241-246.
121. Bregeon F, Papazian L, Visconti A, et al. Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. JAMA 1997, 277:655-662.
122. Rea-Neto A, Youssef NC, Tuche F, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care 2008, 12:R56.
123. Torres A, Jimenez P, Puig de la Bellacasa J, et al. Diagnostic value of nonfluoroscopic percutaneous lung needle aspiration in patients with pneumonia. Chest 1990, 98:840-844.
124. Falguera M, Nogues A, Ruiz-Gonzalez A, et al. Transthoracic needle aspiration in the study of pulmonary infections in patients with HIV. Chest 1994, 106:697-702.
125. Hsu JL, Kuschner WG, Paik J, et al. The diagnostic yield of CT-guided percutaneous lung biopsy in solid organ transplant recipients. Clin Transplant 2012, 26:615-621.
126. Cockerill FR, Wilson WR, Carpenter HA, et al. Open lung biopsy in immunocompromised patients. Arch Intern Med 1985, 145:1398-1404.
127. Kramer MR, Berkman N, Mintz B, et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann Thorac Surg 1998, 65:198-202.
128. Light RW Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006, 3:75-80.
129. Lisboa T, Waterer GW, Lee YC Pleural infection: changing bacteriology and its implications. Respirology 2011, 16:598-603.
130. Li ST, Tancredi DJ Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010, 125:26-33.
131. Sahn SA Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis 2007, 45:1480-1486.
132. Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005, 352:865-874.
133. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011, 30:289-294.
134. Nagesh BS, Sehgal S, Jindal SK, et al. Evaluation of polymerase chain reaction for detection of Mycobacterium tuberculosis in pleural fluid. Chest 2001, 119:1737-1741.
135. Greco S, Girardi E, Masciangelo R, et al. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis 2003, 7:777-786.
136. Liang QL, Shi HZ, Wang K, et al. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med 2008, 102:744-754.
137. Waterer GW, Wunderink RG The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001, 95:78-82.
138. Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169:342-347.
139. Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009, 49:409-416.
140. Bordon J, Peyrani P, Brock GN, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 2008, 133:618-624.
141. Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003, 123:1142-1150.
142. Dedier J, Singer DE, Chang Y, et al. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001, 161:2099-2104.
143. Berk SL Justifying the use of blood cultures when diagnosing community-acquired pneumonia. Chest 1995, 108:891-892.
144. Craven DE Blood cultures for community-acquired pneumonia: piecing together a mosaic for doing less. Am J Respir Crit Care Med 2004, 169:327-328.
145. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001, 33:492-503.
146. Miyashita N, Ouchi K, Kawasaki K, et al. Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydophila pneumoniae. Respirology 2008, 13:427-431.
147. Waites KB, Talkington DF Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004, 17:697-728.
148. Sillis M The limitations of IgM assays in the serological diagnosis of Mycoplasma pneumoniae infections. J Med Microbiol 1990, 33:253-258.
149. Hvidsten D, Halvorsen DS, Berdal BP, et al. Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling. Clin Microbiol Infect 2009, 15:42-49.
150. Venkatesan P, Macfarlane JT Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia. Thorax 1992, 47:329-331.
151. Kee C, Palladino S, Kay I, et al. Feasibility of real-time polymerase chain reaction in whole blood to identify Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:72-75.
152. Smith JA, Kauffman CA Pulmonary fungal infections. Respirology 2012, 17:913-926.
153. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1→3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005, 43:5957-5962.
154. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-beta-d-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012, 50:7-15.
155. Thompson GR, Bays DJ, Johnson SM, et al. Serum (1→3)-beta-d-glucan measurement in coccidioidomycosis. J Clin Microbiol 2012, 50:3060-3062.
156. Sax PE, Komarow L, Finkelman MA, et al. Blood (1→3)-beta-d-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011, 53:197-202.
157. Niederman MS Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008, 47(suppl 3):S127-S132.
158. Christ-Crain M, Muller B Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007, 30:556-573.
159. Povoa P Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008, 21:157-162.
160. Chalmers JD, Singanayagam A, Hill AT C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121:219-225.
161. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
162. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012, 172:715-722.
163. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012, (9).
164. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602.
165. Salluh JI, Bozza FA, Soares M, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest 2008, 134:947-954.
166. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007, 176:913-920.
167. Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001, 119:243-249.
168. Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004, 38:222-226.
169. Ishida T, Hashimoto T, Arita M, et al. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother 2004, 10:359-363.
170. Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003, 21:209-214.
171. Dowell SF, Garman RL, Liu G, et al. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001, 32:824-825.
172. Engel MF, van Velzen M, Hoepelman AI, et al. Positive urinary antigen tests for Streptococcus pneumoniae in community-acquired pneumonia: a 7-year retrospective evaluation of health care cost and treatment consequences. Eur J Clin Microbiol Infect Dis 2013, 32:485-492.
173. Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest 1996, 110:343-350.
174. Boersma WG, Daniels JM, Lowenberg A, et al. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. Respir Med 2006, 100:926-932.
175. Rubinstein E, Kollef MH, Nathwani D Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(suppl 5):S378-S385.
176. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45:315-321.
177. Kim EA, Lee KS, Primack SL, et al. Viral pneumonias in adults: radiologic and pathologic findings. RadioGraphics 2002, 22(spec no):S137-S149.
178. Boroja M, Barrie JR, Raymond GS Radiographic findings in 20 patients with hantavirus pulmonary syndrome correlated with clinical outcome. AJR Am J Roentgenol 2002, 178:159-163.
179. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003, 348:1995-2005.
180. Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003, 228:401-406.
181. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
182. Johnstone J, Majumdar SR, Fox JD, et al. Human metapneumovirus pneumonia in adults: results of a prospective study. Clin Infect Dis 2008, 46:571-574.
183. Hamelin ME, Cote S, Laforge J, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005, 41:498-502.
184. Jartti T, Hedman K, Jartti L, et al. Human bocavirus-the first 5 years. Rev Med Virol 2012, 22:46-64.
185. Hsieh SC, Kuo YT, Chern MS, et al. Mycoplasma pneumonia: clinical and radiographic features in 39 children. Pediatr Int 2007, 49:363-367.
186. Fine NL, Smith LR, Sheedy PF Frequency of pleural effusions in Mycoplasma and viral pneumonias. N Engl J Med 1970, 283:790-793.
187. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977, 297:1189-1197.
188. Pope TL, Armstrong P, Thompson R, et al. Pittsburgh pneumonia agent: chest film manifestations. AJR Am J Roentgenol 1982, 138:237-241.
189. Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998, 27:358-363.
190. Hayden GE, Wrenn KW Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J Emerg Med 2009, 36:266-270.
191. Reynolds JH, McDonald G, Alton H, et al. Pneumonia in the immunocompetent patient. Br J Radiol 2010, 83:998-1009.
192. Love C, Palestro CJ Radionuclide imaging of inflammation and infection in the acute care setting. Semin Nucl Med 2013, 43:102-113.
193. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996, 101:508-515.
194. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990, 69:307-316.
195. Centers for Disease Control and Prevention Legionellosis-United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2011, 60:1083-1086.
196. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995, 152(4 pt 1):1309-1315.
197. Bochud PY, Moser F, Erard P, et al. Community-acquired pneumonia: a prospective outpatient study. Medicine (Baltimore) 2001, 80:75-87.
198. Halm EA, Teirstein AS Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002, 347:2039-2045.
199. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999, 159:970-980.
200. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997, 12:423-430.
201. Marrie TJ, Poulin-Costello M, Beecroft MD, et al. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005, 99:60-65.
202. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001, 56:296-301.
203. File TM Community-acquired pneumonia. Lancet 2003, 362:1991-2001.
204. Albrich WC, Baughman W, Schmotzer B, et al. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44:1569-1576.
205. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369:155-163.
206. Di Sabatino A, Carsetti R, Corazza GR Post-splenectomy and hyposplenic states. Lancet 2011, 378:86-97.
207. Afessa B, Greaves WL, Frederick WR Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 1995, 21:345-351.
208. Dworkin MS, Park L, Borchardt SM The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or =65 years old. Clin Infect Dis 2007, 44:810-816.
209. Mathew J, Addai T, Anand A, et al. Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1995, 155:1641-1648.
210. Naraqi S, McDonnell G Hematogenous staphylococcal pneumonia secondary to soft tissue infection. Chest 1981, 79:173-175.
211. Gillet Y, Etienne J, Lina G, et al. Association of necrotizing pneumonia with Panton-Valentine leukocidin-producing Staphylococcus aureus, regardless of methicillin resistance. Clin Infect Dis 2008, 47:985-986.
212. Kang CI, Song JH, Oh WS, et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2008, 27:657-661.
213. Yu VL, Kroboth FJ, Shonnard J, et al. Legionnaires' disease: new clinical perspective from a prospective pneumonia study. Am J Med 1982, 73:357-361.
214. Neil K, Berkelman R Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis 2008, 47:591-599.
215. Nicotra B, Rivera M, Luman JI, et al. Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch Intern Med 1986, 146:890-893.
216. Donowitz GR, Cox HL Bacterial community-acquired pneumonia in older patients. Clin Geriatr Med 2007, 23:515-534.
217. Koivula I, Sten M, Makela PH Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999, 159:1550-1555.
218. Johnson JC, Jayadevappa R, Baccash PD, et al. Nonspecific presentation of pneumonia in hospitalized older people: age effect or dementia?. J Am Geriatr Soc 2000, 48:1316-1320.
219. Austrian R, Gold J Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-776.
220. Berk SL, Holtsclaw SA, Wiener SL, et al. Nontypeable Haemophilus influenzae in the elderly. Arch Intern Med 1982, 142:537-539.
221. Valenti WM, Trudell RG, Bentley DW Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med 1978, 298:1108-1111.
222. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003, 167:1650-1654.
223. Maruyama T, Niederman MS, Kobayashi T, et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med 2008, 102:1287-1295.
224. Falsey AR, Walsh EE Viral pneumonia in older adults. Clin Infect Dis 2006, 42:518-524.
225. Johnstone J, Majumdar SR, Fox JD, et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008, 134:1141-1148.
226. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008, 63:42-48.
227. Ishizuka S, Yamaya M, Suzuki T, et al. Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis 2003, 188:1928-1939.
228. Mylotte JM Nursing home-acquired pneumonia. Clin Infect Dis 2002, 35:1205-1211.
229. Chan Carusone SB, Walter SD, Brazil K, et al. Pneumonia and lower respiratory infections in nursing home residents: predictors of hospitalization and mortality. J Am Geriatr Soc 2007, 55:414-419.
230. Mylotte JM Nursing home-associated pneumonia. Clin Geriatr Med 2007, 23:553-565.
231. Quagliarello V, Ginter S, Han L, et al. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis 2005, 40:1-6.
232. Hicks LA, Shepard CW, Britz PH, et al. Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus. J Am Geriatr Soc 2006, 54:284-289.
233. Strausbaugh LJ, Sukumar SR, Joseph CL Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Clin Infect Dis 2003, 36:870-876.
234. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
235. Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia: etiology, prognosis, and treatment. Am Rev Respir Dis 1990, 142:369-373.
236. Rello J, Quintana E, Ausina V, et al. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993, 103:232-235.
237. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011, 11:76.
238. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008, 12:R28.
239. Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013, 144:258-265.
240. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996, 275:134-141.
241. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51:1010-1016.
242. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
243. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006, 27:151-157.
244. Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174:1249-1256.
245. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384.
246. Labarere J, Schuetz P, Renaud B, et al. Validation of a clinical prediction model for early admission to the intensive care unit of patients with pneumonia. Acad Emerg Med 2012, 19:993-1003.
247. Venditti M, Falcone M, Corrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26. Study Group of the Italian Society of Internal Medicine.
248. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
249. Reimann HA An acute infection of the respiratory tract with atypical pneumonia: a disease entity probably caused by a filtrable virus. JAMA 1938, 111:2377-2384.
250. Hohenthal U, Vainionpaa R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008, 40:131-138.
251. Falguera M, Sacristan O, Nogues A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001, 161:1866-1872.
252. Ruiz-Gonzalez A, Falguera M, Nogues A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999, 106:385-390.
253. Miyashita N, Ouchi K, Kawasaki K, et al. Mycoplasma pneumoniae pneumonia in the elderly. Med Sci Monit 2008, 14:CR387-CR391.
254. Miyashita N, Obase Y, Ouchi K, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007, 56(pt 12):1625-1629.
255. File TM, Plouffe JF, Breiman RF, et al. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis 1999, 29:426-428.
256. Grayston JT Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992, 15:757-761.
257. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995, 172:389-394.
258. Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010, 138:811-816.
259. Garcia-Garcia ML, Calvo C, Pozo F, et al. Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J 2012, 31:808-813.
260. Choi SH, Hong SB, Ko GB, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012, 186:325-332.
261. Pretorius MA, Madhi SA, Cohen C, et al. Respiratory viral coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness-South Africa, 2009-2010. J Infect Dis 2012, 206(suppl 1):S159-S165.
262. Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet 2011, 377:1264-1275.
263. Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002, 186:127-128.
264. Stout JE, Yu VL Legionellosis. N Engl J Med 1997, 337:682-687.
265. Reza Shariatzadeh M, Huang JQ, Marrie TJ Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006, 54:296-302.
266. Matthay MA, Rosen GD Acid aspiration induced lung injury: new insights and therapeutic options. Am J Respir Crit Care Med 1996, 154(2 pt 1):277-278.
267. Marik PE Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001, 344:665-671.
268. Rabinovici R, Neville LF, Abdullah F, et al. Aspiration-induced lung injury: role of complement. Crit Care Med 1995, 23:1405-1411.
269. Finegold SM Aspiration pneumonia. Rev Infect Dis 1991, 13(suppl 9):S737-S742.
270. Bartlett JG Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993, 16(suppl 4):S248-S255.
271. Cottin V, Cordier JF Eosinophilic pneumonias. Allergy 2005, 60:841-857.
272. Allen JN, Davis WB Eosinophilic lung diseases. Am J Respir Crit Care Med 1994, 150:1423-1438.
273. Philit F, Etienne-Mastroianni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002, 166:1235-1239.
274. Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia: a clinical and follow-up study of 62 cases. Groupe d'Études et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1998, 77:299-312.
275. Agarwal R Allergic bronchopulmonary aspergillosis. Chest 2009, 135:805-826.
276. Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013, 19:216-228.
277. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004, 53(RR-3):1-36.
278. Stone PW, Kunches L, Hirschhorn L Cost of hospital-associated infections in Massachusetts. Am J Infect Control 2009, 37:210-214.
279. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998, 129:433-440.
280. Bonten MJ, Gaillard CA, de Leeuw PW, et al. Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia. Clin Infect Dis 1997, 24:309-319.
281. Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007, 28:825-831.
282. Bartlett JG, O'Keefe P, Tally FP, et al. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986, 146:868-871.
283. Dore P, Robert R, Grollier G, et al. Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Am J Respir Crit Care Med 1996, 153(4 pt 1):1292-1298.
284. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(suppl 3):iii1-iii55.
285. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998, 20:820-837.
286. Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005, 142:165-172.
287. Coley CM, Li YH, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med 1996, 156:1565-1571.
288. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000, 283:749-755.
289. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998, 158:1350-1356.
290. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010, 65:878-883.
291. Chalmers JD, Akram AR, Hill AT Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011, 37:858-864.
292. Fang WF, Yang KY, Wu CL, et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care 2011, 15:R32.
293. Carrabba M, Zarantonello M, Bonara P, et al. Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression. Eur Respir J 2012, 40:1201-1210.
294. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011, 53:503-511.
295. Baldwin DR, Honeybourne D, Wise R Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992, 36:1176-1180.
296. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
297. Craig WA Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
298. Jacobs MR Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001, 7:589-596.
299. Moore RD, Smith CR, Lietman PS Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984, 77:657-662.
300. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
301. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
302. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
303. Deresinski S Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007, 44:1543-1548.
304. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011, 66(suppl 2):ii1-ii23.
305. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011, 53:e25-e76.
306. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
307. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001, 32:701-707.
308. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005, 40:1288-1297. Toronto Invasive Bacterial Disease Network.
309. Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006, 43:432-438. Toronto Invasive Bacterial Diseases Network.
310. Daneman N, Low DE, McGeer A, et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008, 46:1131-1138.
311. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55:371-380.
312. Asadi L, Eurich DT, Gamble JM, et al. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012, 106:451-458.
313. Asadi L, Eurich DT, Gamble JM, et al. Impact of guideline-concordant antibiotics and macrolide/beta-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect 2013, 19:257-264.
314. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
315. Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013, 368:1665-1668.
316. Svanstrom H, Pasternak B, Hviid A Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013, 368:1704-1712.
317. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
318. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
319. Saravolatz LD, Stein GE, Johnson LB Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011, 52:1156-1163.
320. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35:1888-1895.
321. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744. Canadian Critical Care Trials Group.
322. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748.
323. Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498.
324. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
325. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
326. Welker JA, Huston M, McCue JD Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008, 168:351-356.
327. Nicks BA, Manthey DE, Fitch MT The Centers for Medicare and Medicaid Services (CMS) community-acquired pneumonia core measures lead to unnecessary antibiotic administration by emergency physicians. Acad Emerg Med 2009, 16:184-187.
328. Quattromani E, Powell ES, Khare RK, et al. Hospital-reported data on the pneumonia quality measure "Time to First Antibiotic Dose" are not associated with inpatient mortality: results of a nationwide cross-sectional analysis. Acad Emerg Med 2011, 18:496-503.
329. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
330. Rice LB The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008, 46:491-496.
331. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279:1452-1457.
332. Akram AR, Chalmers JD, Taylor JK, et al. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 2013, 19:1174-1180.
333. Hitt CM, Nightingale CH, Quintiliani R, et al. Streamlining antimicrobial therapy for lower respiratory tract infections. Clin Infect Dis 1997, 24(suppl 2):S231-S237.
334. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001, 111:367-374.
335. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006, 333:1193.
336. Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006, 119:512.e1-512.e7.
337. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002, 162:1278-1284.
338. Capelastegui A, Espana Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest 2009, 136:1079-1085.
339. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007, 120:783-790.
340. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006, 332:1355.
341. Frei CR, Restrepo MI, Mortensen EM, et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006, 119:865-871.
342. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009, 169:1515-1524.
343. McCabe C, Kirchner C, Zhang H, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009, 169:1525-1531.
344. Webb BJ, Dangerfield BS, Pasha JS, et al. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med 2012, 106:1606-1612.
345. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intra-venous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003, 115:343-351.
346. Carratala J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012, 172:922-928.
347. Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008, 46:550-556.
348. Amsden GW Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 2005, 55:10-21.
349. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexa-methasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377:2023-2030.
350. Shafiq M, Mansoor MS, Khan AA, et al. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med 2013, 8:68-75.
351. Chopra V, Flanders SA Does statin use improve pneumonia outcomes?. Chest 2009, 136:1381-1388.
352. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39:1871-1878.
353. Siempos II, Vardakas KZ, Kopterides P, et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008, 62:661-668.
354. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995, 123:518-527.
355. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.
356. Centers for Disease Control and Prevention Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012, 61:613-618.
357. Johnstone J, Eurich DT, Minhas JK, et al. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010, 51:15-22.
358. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, (1).
359. Almirall J, Bolibar I, Balanzo X, et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999, 13:349-355.
360. Cecere LM, Williams EC, Sun H, et al. Smoking cessation and the risk of hospitalization for pneumonia. Respir Med 2012, 106:1055-1062.
361. Mizgerd JP Acute lower respiratory tract infection. N Engl J Med 2008, 358:716-727.
362. Metlay JP, Kapoor WN, Fine MJ Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997, 278:1440-1445.
363. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997, 157:1453-1459.
364. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-1718.
365. Chertow DS, Memoli MJ Bacterial coinfection in influenza: a grand rounds review. JAMA 2013, 309:275-282.
366. Johansson N, Kalin M, Hedlund J Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011, 43:609-615.
367. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medical Association of the Infectious Diseases Society of America. Available at, Accessed May 7, 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
368. Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003, 82:159-169.
369. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
370. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007, 167:1393-1399.
371. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010, 50:202-209.
372. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
373. Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000, 31:869-874.
374. Musher DM, Montoya R, Wanahita A Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004, 39:165-169.
375. Murdoch DR Diagnosis of Legionella infection. Clin Infect Dis 2003, 36:64-69.
376. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006, 355:2619-2630. Canadian Critical Care Trials Group.
377. Light RW Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006, 3:75-80.
378. Sahn SA Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis 2007, 45:1480-1486.
379. Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009, 49:409-416.
380. Waites KB, Talkington DF Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004, 17:697-728.
381. Smith JA, Kauffman CA Pulmonary fungal infections. Respirology 2012, 17:913-926.
382. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-beta-d-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012, 50:7-15.
383. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012, (9).
384. Boersma WG, Daniels JM, Lowenberg A, et al. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. Respir Med 2006, 100:926-932.
385. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996, 101:508-515.
386. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990, 69:307-316.
387. Bochud PY, Moser F, Erard P, et al. Community-acquired pneumonia: a prospective outpatient study. Medicine (Baltimore) 2001, 80:75-87.
388. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999, 159:970-980.
389. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003, 167:1650-1654.
390. Johnstone J, Majumdar SR, Fox JD, et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008, 134:1141-1148.
391. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
392. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
393. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006, 27:151-157.
394. File TM, Plouffe JF, Breiman RF, et al. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis 1999, 29:426-428.
395. Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010, 138:811-816.
396. Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet 2011, 377:1264-1275.
397. Stout JE, Yu VL Legionellosis. N Engl J Med 1997, 337:682-687.
398. Reza Shariatzadeh M, Huang JQ, Marrie TJ Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006, 54:296-302.
399. Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013, 19:216-228.
400. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(suppl 3):iii1-iii55.
401. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
402. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011, 66(suppl 2):ii1-ii23.
403. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011, 53:e25-e76.
404. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744. Canadian Critical Care Trials Group.
405. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
406. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279:1452-1457.
407. Capelastegui A, Espana Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest 2009, 136:1079-1085.
408. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003, 115:343-351.
409. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.